1. FDA. Guidance for industry PAT—a framework for innovative pharmaceutical development, manufacturing, and quality assurance. 2004. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070305.pdf . Accessed 4 Aug 2009.
2. FDA CDER. Draft guidance for industry metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and controls documentation. 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070573.pdf . Accessed 4 Aug 2009.
3. EP 2.9.18. Preparations for inhalations: aerodynamic assessment of fine particles. Strasbourg: Council of Europe; 2008.
4. USP 31. Chapter <601> aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Rockville: USP; 2008.
5. Health Canada. Pharmaceutical quality of inhalation and nasal products. 2006. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/chem/inhalationnas_e.html (Accessed 4 Aug 2009) and EMEA. 2006 EMEA/CHMP/QWP/49313/2005 Corr. http://www.emea.europa.eu/pdfs/human/qwp/4931305en.pdf (Accessed 4 Aug 2009). Also adopted by Australia: http://www.tga.gov.au/docs/pdf/euguide/qwp/4931305en.pdf . Accessed 4 May 2009.